Durable Response With Insulin Pump Therapy in T2DM

This article originally appeared here.
Share this content:
Durable Response With Insulin Pump Therapy in T2DM
Durable Response With Insulin Pump Therapy in T2DM

THURSDAY, Feb. 11, 2016 (HealthDay News) -- Insulin pump therapy is more effective than multiple daily injections (MDI) for glycemic control in patients with type 2 diabetes, according to a study published online Feb. 8 in Diabetes, Obesity and Metabolism.

Ronnie Aronson, M.D., from LMC Diabetes & Endocrinology in Toronto, and colleagues compared insulin pump therapy and MDI in 331 patients with type 2 diabetes. Participants with glycated hemoglobin ≥8.0 percent and ≤12 percent were randomly allocated to pump therapy or continued MDI in a six-month randomization phase (RP). During a six-month continuation phase (CP), the MDI group was switched to pump therapy.

The researchers found that the reduction in glycated hemoglobin was significantly greater with pump therapy versus MDI at the end of the RP (−1.1 ± 1.2 versus −0.4 ± 1.1 percent; P < 0.001). This improvement was maintained to 12 months. A 0.8 percent reduction in glycated hemoglobin was seen for the MDI patients who switched to pump therapy; the final glycated hemoglobin was identical between the groups. The total daily insulin dose (TDD) was 20.4 percent lower with pump therapy than MDI in the RP, and persisted in the CP. There was a 19 percent decline in TDD in the MDI group, so that by 12 months TDD was the same in both groups.

"Patients with refractory hyperglycemia on a current basal-prandial injection regimen should be considered appropriate candidates for pump therapy, and may obtain sustained glycemic control with a favorable safety profile and reduction of insulin dose," the authors write.

Several authors disclosed financial ties to pharmaceutical and medical technology companies, including Medtronic, which funded the study; several authors disclosed full-time employment by Medtronic.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »